NCT01815528View on ClinicalTrials.gov

Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions

Recurrent Epithelial Ovarian Cancer

Interventions

DRUG

Catumaxomab

"Catumaxomab dosing comprises the following four intraperitoneal (i.p.) infusions via an i.p.-port or an indwelling catheter:~1. 10 µg on day 0~2. 20 µg on day 3~3. 50 µg on day 7~4. 150 µg on day 10"

Trial Locations (1)

13353

Charité Campus Virchow-Klinikum, Berlin